Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dianhydrogalactitol - Kintara Therapeutics

Drug Profile

Dianhydrogalactitol - Kintara Therapeutics

Alternative Names: DAG for Injection; Dianhydrodulcitol; Diepoxydulcitol; Diepoxygalactitol; NSC-1323313; VAL-083

Latest Information Update: 29 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DelMar Pharmaceuticals
  • Developer DelMar Pharmaceuticals; Global Coalition for Adaptive Research; Guangxi Wuzhou Pharmaceutical; Kintara Therapeutics; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatics; Epoxy compounds; Ethylene glycols; Small molecules
  • Mechanism of Action Alkylating agents; BRD4 protein inhibitors; Cell cycle inhibitors; DNA damage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Ovarian cancer; Medulloblastoma; Diffuse intrinsic pontine glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Lung cancer
  • Suspended Diffuse intrinsic pontine glioma; Glioblastoma; Medulloblastoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 22 Nov 2023 Kintara Therapeutics completes an expanded access program trial in Cancer (NCT03138629)
  • 03 Nov 2023 Chemical structure information added
  • 31 Oct 2023 Suspended - Clinical-Phase-Unknown for Haematological malignancies in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top